Every material Form 8-K Neurogene Inc. has filed with the SEC since November 09, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Neurogene Inc. reported third quarter 2026 results, with a net loss of $29.0 million for the three months ended September 30, 2026, up from $21.0 million a year earlier. Higher R&D and G&A spending, driven largely by NGN-401 development and stock-based compensation, drove the increase, and the company said its cash position is expected to fund operations into the first quarter of 2029.
Net loss was $29.0 million for Q3 2026, compared with $21.0 million for Q3 2025.
R&D expenses rose to $23.5 million from $17.2 million, mainly for NGN-401 clinical trial and manufacturing activities.
G&A expenses rose to $8.9 million from $6.6 million, mainly from higher non-cash stock-based compensation.
Cash, cash equivalents and short-term investments were $359.7 million as of September 30, 2026, expected to fund operations into the first quarter of 2029.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Neurogene Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →